Hormone Resistant Prostate Cancer Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel
Conditions: Prostate Cancer; Metastatic Prostate Carcinoma; Prostate Adenocarcinoma; Stage IV Prostate CancerInterventions: Drug: Dexamethasone; Drug: Enzalutamide; Other: Laboratory Biomarker Analysis; Other: Quality-of-Life AssessmentSponsors: Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI)Not yet recruiting - verified July 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 18, 2015 Category: Research Source Type: clinical trials

NaF/FDG PET/MRI in Measuring Response to Radium Ra 223 Dichloride in Patients With Metastatic Hormone-Resistant Prostate Cancer
Conditions: Hormone-Resistant Prostate Cancer; Metastatic Malignant Neoplasm in the Bone; Metastatic Prostate CarcinomaInterventions: Procedure: Contrast-enhanced Magnetic Resonance Imaging; Radiation: Fludeoxyglucose F-18; Radiation: Fluorine F 18 Sodium Fluoride; Procedure: Magnetic Resonance Imaging; Procedure: Positron Emission TomographySponsors: Stanford University; National Cancer Institute (NCI)Recruiting - verified May 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 17, 2015 Category: Research Source Type: clinical trials